Retatrutide and trizepatide constitute a new class of medications that act on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor https://elodieypec031549.blogocial.com/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide-74588097